Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017 – Nasdaq
|
Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
Nasdaq SYDNEY, Australia, Oct. 31, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Medical Officer, gave an oral presentation at the World … |
|
Revolutionary Stem Cell Therapy for Knees, Also Known as Living ‘bandage’
Markets Insider Now, a new form of living ‘bandage’ using stem cell therapy is being trialed in humans, using technology developed by scientists in the Universities of Bristol and Liverpool in the UK. An initial form of the bandage has already been tested in five … |
|
Revolutionary Stem Cell Therapy for Knees, Also Known as Living ‘bandage’
Markets Insider Now, a new form of living ‘bandage’ using stem cell therapy is being trialed in humans, using technology developed by scientists in the Universities of Bristol and Liverpool in the UK. An initial form of the bandage has already been tested in five … |
|
Revolutionary Stem Cell Therapy for Knees, Also Known as Living ‘bandage’
Markets Insider Now, a new form of living ‘bandage’ using stem cell therapy is being trialed in humans, using technology developed by scientists in the Universities of Bristol and Liverpool in the UK. An initial form of the bandage has already been tested in five … |
|
Voyager down 7% on Genzyme exit from Parkinson’s gene therapy program
Seeking Alpha Voyager Therapeutics (VYGR -7%) will likely end the day in the red after reporting that collaboration partner Sanofi Genzyme (SNY -0.2%) decided not to exercise its ex-U.S. rights to develop and commercialize gene therapy candidate VY-AADC for advanced … |
|
Voyager down 7% on Genzyme exit from Parkinson’s gene therapy program
Seeking Alpha Voyager Therapeutics (VYGR -7%) will likely end the day in the red after reporting that collaboration partner Sanofi Genzyme (SNY -0.2%) decided not to exercise its ex-U.S. rights to develop and commercialize gene therapy candidate VY-AADC for advanced … |